[go: up one dir, main page]

MX2017002858A - Sales novedosas de 3-[(dimetilamino)metil]-n-{2-[4-(hidroxicarbamo il)fenoxi]etil}-1-benzofuran-2-carboxamida, formas cristalinas relacionadas, metodo para preparar las mismas y las composiciones farmaceuticas que contiene las mismas. - Google Patents

Sales novedosas de 3-[(dimetilamino)metil]-n-{2-[4-(hidroxicarbamo il)fenoxi]etil}-1-benzofuran-2-carboxamida, formas cristalinas relacionadas, metodo para preparar las mismas y las composiciones farmaceuticas que contiene las mismas.

Info

Publication number
MX2017002858A
MX2017002858A MX2017002858A MX2017002858A MX2017002858A MX 2017002858 A MX2017002858 A MX 2017002858A MX 2017002858 A MX2017002858 A MX 2017002858A MX 2017002858 A MX2017002858 A MX 2017002858A MX 2017002858 A MX2017002858 A MX 2017002858A
Authority
MX
Mexico
Prior art keywords
same
benzofuran
carboxamide
dimethylamino
ethyl
Prior art date
Application number
MX2017002858A
Other languages
English (en)
Inventor
Gaillard Marina
Letellier Philippe
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1458224A external-priority patent/FR3025197B1/fr
Priority claimed from FR1458215A external-priority patent/FR3025196B1/fr
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of MX2017002858A publication Critical patent/MX2017002858A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01V—GEOPHYSICS; GRAVITATIONAL MEASUREMENTS; DETECTING MASSES OR OBJECTS; TAGS
    • G01V3/00—Electric or magnetic prospecting or detecting; Measuring magnetic field characteristics of the earth, e.g. declination, deviation
    • G01V3/14—Electric or magnetic prospecting or detecting; Measuring magnetic field characteristics of the earth, e.g. declination, deviation operating with electron or nuclear magnetic resonance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Neurology (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geology (AREA)
  • Geophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Remote Sensing (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Environmental & Geological Engineering (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Sales novedosas de 3-[(dimetilamino)metil]-n-(2 [4- (hidroxicarbamoil)fenoxi]etil]-l-benzofuran-2-carboxamida, formas cristalinas relacionadas, método para preparar las mismas y las composiciones farmacéuticas que contienen las mismas a Se describen en el presente documento sales de 3- [(dimetilamino)metil]-/V-{2-E4-(hidroxicarbamoil)fenoxiietill-1 benzofuran 2-carboxamida, en particular de formula (I): (ver formula I) en la que HA es ácido naftaleno-1,5 disulfónico, Acido naftaleno-2-sulf6nico, Acido oxálico, Acido bencenosulfónico o ácido sulfúrico, o hidratos de los mismos, y formas cristalinas de los mismos caracterizadas por el diagrama de difracción de rayos X en polvo y el espectro de RMN CP/MAS 13C en estado sólido. También se describen composiciones, métodos de use o preparación de los mismos.
MX2017002858A 2014-09-03 2015-09-03 Sales novedosas de 3-[(dimetilamino)metil]-n-{2-[4-(hidroxicarbamo il)fenoxi]etil}-1-benzofuran-2-carboxamida, formas cristalinas relacionadas, metodo para preparar las mismas y las composiciones farmaceuticas que contiene las mismas. MX2017002858A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1458224A FR3025197B1 (fr) 2014-09-03 2014-09-03 Nouveau sel de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR1458215A FR3025196B1 (fr) 2014-09-03 2014-09-03 Nouveaux sels de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/US2015/048243 WO2016036910A1 (en) 2014-09-03 2015-09-03 Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same

Publications (1)

Publication Number Publication Date
MX2017002858A true MX2017002858A (es) 2017-10-24

Family

ID=54186276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002858A MX2017002858A (es) 2014-09-03 2015-09-03 Sales novedosas de 3-[(dimetilamino)metil]-n-{2-[4-(hidroxicarbamo il)fenoxi]etil}-1-benzofuran-2-carboxamida, formas cristalinas relacionadas, metodo para preparar las mismas y las composiciones farmaceuticas que contiene las mismas.

Country Status (10)

Country Link
US (2) US20170266151A1 (es)
EP (1) EP3189040B1 (es)
JP (1) JP2017530106A (es)
KR (1) KR20170043648A (es)
CN (1) CN107001307A (es)
AU (1) AU2015311905B2 (es)
CA (1) CA2960044A1 (es)
MX (1) MX2017002858A (es)
SG (2) SG11201701674RA (es)
WO (1) WO2016036910A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017002858A (es) 2014-09-03 2017-10-24 Pharmacyclics Llc Sales novedosas de 3-[(dimetilamino)metil]-n-{2-[4-(hidroxicarbamo il)fenoxi]etil}-1-benzofuran-2-carboxamida, formas cristalinas relacionadas, metodo para preparar las mismas y las composiciones farmaceuticas que contiene las mismas.
EP4351734A1 (en) * 2021-06-10 2024-04-17 Teva Pharmaceuticals International GmbH Solid state forms of abexinostat and process for preparation thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038004A (en) 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
GB0020721D0 (en) 2000-08-22 2000-10-11 Merck Sharp & Dohme Therapeutic agents
WO2004092115A2 (en) * 2003-04-07 2004-10-28 Axys Pharmaceuticals Inc. Hydroxamates as therapeutic agents
CN101337933B (zh) 2003-12-25 2011-03-02 卫材R&D管理有限公司 喹啉羧酰胺的甲磺酸盐的结晶(a)及其制备方法
US8702670B2 (en) 2004-06-30 2014-04-22 Mcneil-Ppc, Inc. Intravaginal device with controlled expansion
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8603521B2 (en) * 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
AU2010299483B2 (en) 2009-09-24 2014-08-28 Sun Pharmaceutical Industries Limited Process for the preparation of sorafenib tosylate
ES2842970T3 (es) * 2011-03-09 2021-07-15 Cereno Scient Ab Compuestos y métodos para mejorar la fibrinólisis endógena alterada usando inhibidores de la histona desacetilasa
FR2977492B1 (fr) 2011-07-04 2013-07-05 Servier Lab Nouvelle association entre le n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide et le folfox
WO2013039956A2 (en) 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating mood disorders
CN102531964B (zh) * 2011-10-10 2014-06-11 华东理工大学 具有抗肿瘤作用的二元羧酸衍生物及制备方法
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX2017002858A (es) 2014-09-03 2017-10-24 Pharmacyclics Llc Sales novedosas de 3-[(dimetilamino)metil]-n-{2-[4-(hidroxicarbamo il)fenoxi]etil}-1-benzofuran-2-carboxamida, formas cristalinas relacionadas, metodo para preparar las mismas y las composiciones farmaceuticas que contiene las mismas.

Also Published As

Publication number Publication date
US20200069637A1 (en) 2020-03-05
AU2015311905A1 (en) 2017-03-23
KR20170043648A (ko) 2017-04-21
SG11201701674RA (en) 2017-04-27
JP2017530106A (ja) 2017-10-12
US20170266151A1 (en) 2017-09-21
AU2015311905B2 (en) 2020-03-05
CA2960044A1 (en) 2016-03-10
SG10201901916WA (en) 2019-04-29
EP3189040B1 (en) 2020-07-29
EP3189040A1 (en) 2017-07-12
WO2016036910A1 (en) 2016-03-10
US10898461B2 (en) 2021-01-26
CN107001307A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
PH12017500361A1 (en) Novel compounds
PH12016500169A1 (en) Polymorph of syk inhibitors
MY160785A (en) Manufacturing process for pyrimidine derivatives
WO2015114395A9 (en) Process for the preparation of vortioxetine salts
EP4606784A3 (en) Co-crystals, salts and solid forms of tenofovir alafenamide
MY192027A (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
ZA201805185B (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
MX2015009617A (es) Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.
MX2017002858A (es) Sales novedosas de 3-[(dimetilamino)metil]-n-{2-[4-(hidroxicarbamo il)fenoxi]etil}-1-benzofuran-2-carboxamida, formas cristalinas relacionadas, metodo para preparar las mismas y las composiciones farmaceuticas que contiene las mismas.
BR112016021910A2 (pt) Processo de preparação de 3-(3-(4-(1-aminociclobutil)fenil)-5-fenil-3h-imidazo[4,5-b]piridin-2-il)piridin-2-amina
UA111334C2 (uk) Дельта-кристалічна форма аргінінової солі периндроприлу, спосіб її одержання і фармацевтична композиція, яка її містить
EA201790522A1 (ru) Соль производного цефалоспорина, ее кристаллическое твердое вещество и способ ее получения
WO2014195593A3 (fr) Composes inhibiteurs de l'acetylcholinesterase et agonistes des recepteurs serotoninergiques 5ht4, a effet promnesiant, leurs procedes de preparation et compositions pharmaceutiques les contenant
MX375758B (es) Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido.
MX2016014948A (es) Sales derivadas de bencisoxazol.
WO2014167509A3 (en) Loxoprofen polymorphs and process for preparation of the same
WO2016051422A3 (en) Process for the preparation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide and its polymorphs thereof
MX2015006806A (es) Procedimiento para preparar 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1 -oxido-4-piridil)-5-metoxipiridina-2-carboxamida.
HK1240926A1 (en) Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
PL410320A1 (pl) Nowe czwartorzędowe alkoksymetylowe chlorki propikonazolu, sposób ich wytwarzania oraz zastosowanie jako inhibitory wzrostu patogenów grzybowych
PL410319A1 (pl) Nowe czwartorzędowe alkoksymetylowe chlorki tebukonazolu, sposób ich wytwarzania oraz zastosowanie jako inhibitory wzrostu grzybni
PL399182A1 (pl) Sposób wytwarzania nilotinibu
NZ629866A (en) Solid forms comprising 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, and a coformer, compositions and methods of use thereof
HK1232527A1 (en) Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]- phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
TN2013000094A1 (en) Manufacturing process for pyrimidine derivatives